Clik here to view.
Clik here to view.
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market...
View ArticleClik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain...
RAHWAY, N.J. Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved new indications for...
View ArticleClik here to view.
MesoPher Cell Therapy Increases 2-Year RFS Rate in Resected Pancreatic Cancer...
‘S-HERTOGENBOSCH, The Netherlands Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, announces publication of the results of a phase II trial in...
View ArticleClik here to view.
がん領域の世界的イノベーション企業であるベイジーン、シャリニ・シャープを役員に任命
カリフォルニア州、サンマテオ （ビジネスワイヤ） — がん領域におけるグローバル企業であるベイジーン（NASDAQ：BGNE、HKEX：06160、SSE：688235）は、2024年9月27日付で、シャリニ・シャープを同社の役員および取締役会監査役に任命したことを発表しました。...
View ArticleClik here to view.
Estrella Immunopharma 首例接受靶向CD19的ARTEMIS® T 细胞疗法的患者达到了完全缓解
EMERYVILLE, Calif (美国商业资讯)– Estrella Immunopharma, Inc.（纳斯达克代码：ESLA，ESLAW）（“Estrella”或“公司”），是一家处于临床阶段的生物制药公司，专注开发针对癌症和自体免疫疾病的，靶向 CD19 和 CD22 的 ARTEMIS® T 细胞疗法。公司今日宣布，首例参与 STARLIGHT-1 I/II...
View ArticleClik here to view.
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta®...
SHANGHAI, China & JERSEY CITY, N.J. Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta®...
View ArticleClik here to view.
Perjeta®（帕妥珠单抗）生物类似药HLX11临床III期对照研究达到主要研究终点
中国上海和新泽西州泽西市 (美国商业资讯)– Shanghai Henlius Biotech, Inc. (2696.HK) 和Organon (NYSE: OGN)...
View ArticleClik here to view.
パージェタ（Perjeta®）（ペルツズマブ）バイオシミラー候補HLX11の第3相比較臨床試験で主要評価項目を達成
中国上海、ニュージャージー州ジャージーシティ （ビジネスワイヤ） —...
View ArticleClik here to view.
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki)...
View ArticleClik here to view.
Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and...
SAN DIEGO Crown Bioscience, a global contract research organization (CRO) headquartered in San Diego, California in the United States, and a part of JSR Life Sciences and JSR Corporation, recently...
View ArticleClik here to view.
癌症治疗：AOP Health研究靶向癌症干细胞的新方法
维也纳 (美国商业资讯)– AOP Orphan Pharmaceuticals GmbH (AOP Health) 与Leukos Biotech的合作迈向了一个重要的里程碑。SERONCO-1一期临床试验纳入首例患者，该试验旨在研究一种具有新颖独特作用机制（同类首创）的物质。该候选药物正在实体瘤和淋巴瘤患者中进行研究。AOP...
View ArticleClik here to view.
がん治療：AOPヘルス、がん幹細胞を標的とした新たなアプローチを研究
ウィーン （ビジネスワイヤ） — AOP Orphan Pharmaceuticals GmbH（AOPヘルス）はLeukos...
View ArticleClik here to view.
Crown Bioscienceが高度なオンコロジーモデルとイメージング機能を備えたシンガポールの施設を拡張
米国サンディエゴ （ビジネスワイヤ） — 米国カリフォルニア州サンディエゴに本社を置き、JSRライフサイエンスおよび日本に本社を置くJSR株式会社傘下の世界的医薬品開発業務受託機関（CRO）であるCrown...
View ArticleClik here to view.
Crown Bioscience扩大新加坡设施并提供先进的肿瘤模型和成像能力
圣迭戈 (美国商业资讯)– Crown Bioscience是一家总部位于美国加利福尼亚州圣迭戈的全球合同研究机构（CRO），并隶属于JSR Life Sciences和总部位于日本的JSR Corporation。该公司今天宣布扩大其位于新加坡的设施。 本次升级包括新的肿瘤研究模型和先进的成像技术。...
View ArticleClik here to view.
Empowering Patient-Centered Care: Oneview and Epworth HealthCare’s Expanded...
MELBOURNE, Australia Oneview Healthcare is thrilled to announce the expansion of its partnership with Epworth HealthCare, aiming to enhance the patient experience by bringing Oneview’s Care...
View ArticleClik here to view.
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
VICTORIA, British Columbia & ZHUHAI, China ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, and Biotheus Inc....
View ArticleClik here to view.
Orum Therapeutics Submits Registration Statement for KOSDAQ Listing
DAEJEON, South Korea & BOSTON Orum Therapeutics (“Orum” or the “Company”), a biopharmaceutical company pioneering the field of degrader-antibody conjugates (DACs) based on its Dual-Precision...
View ArticleClik here to view.
Global Healthy Living Foundation Partners with The Bone Bus to Enhance Rural...
UPPER NYACK, N.Y. & SYDNEY The Global Healthy Living Foundation Australia (GHLF Australia) is proud to announce its collaboration with The Bone Bus, an Australian traveling bone density...
View ArticleClik here to view.
Ferring Pharmaceuticals bolsters global gene therapy supply chain with...
SAINT-PREX, Switzerland Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene...
View Article